Human interleukin-2
- Generic Name
- Human interleukin-2
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- FNO32LO217
- Background
Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).
- Associated Conditions
- -
- Associated Therapies
- -
Prophylaxis Roles of IL-2 Treatment on GVHD After Transplantation
- First Posted Date
- 2016-01-20
- Last Posted Date
- 2020-10-01
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT02659657
- Locations
- 🇨🇳
Peking University Institute of Hematology, Beijing, Beijing, China
Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
- First Posted Date
- 2016-01-11
- Last Posted Date
- 2023-01-19
- Target Recruit Count
- 11
- Registration Number
- NCT02652455
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome（MAS）
- First Posted Date
- 2015-10-06
- Last Posted Date
- 2015-10-06
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT02569463
- Locations
- 🇨🇳
Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, Beijing, China
TIL Therapy for Metastatic Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-06-25
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- Inge Marie Svane
- Target Recruit Count
- 6
- Registration Number
- NCT02482090
- Locations
- 🇩🇰
Center for Cancer Immune Therapy Dept. of Hematology/oncology, Copenhagen, Herlev, Denmark
Peginterferon and TIL Therapy for Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2015-03-04
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Inge Marie Svane
- Target Recruit Count
- 12
- Registration Number
- NCT02379195
- Locations
- 🇩🇰
Center for Cancer Immune Therapy, Dept. of Haematology/Oncology, Copenhagen, Herlev, Denmark
Vemurafenib and TIL Therapy for Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- Inge Marie Svane
- Target Recruit Count
- 13
- Registration Number
- NCT02354690
- Locations
- 🇩🇰
Center for Cancer Immune Therapy, Dept. of Haematology/Oncology, Copenhagen, Herlev, Denmark
A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD
- Conditions
- Interventions
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 25
- Registration Number
- NCT02340676
- Locations
- 🇺🇸
Dana-Farber Cancer Insitute, Boston, Massachusetts, United States
Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD
- First Posted Date
- 2014-12-17
- Last Posted Date
- 2020-06-23
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 21
- Registration Number
- NCT02318082
- Locations
- 🇺🇸
Dana-Farber Cancer Insitute, Boston, Massachusetts, United States
Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2014-10-30
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 168
- Registration Number
- NCT02278887
- Locations
- 🇳🇱
Netherlands Cancer Institute, Amsterdam, NH, Netherlands
🇩🇰CCIT Department of Oncology and Haematology Herlev Hospital, Copenhagen, Denmark
Low-dose IL-2( Interleukin-2) Treatment in SLE
- First Posted Date
- 2014-03-11
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT02084238
- Locations
- 🇨🇳
Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.